2月24日 - ** 制药商百时美施贵宝BMY.N股价上涨3.2%，报57.61美元
** 该公司称， (link)，美国食品和药物管理局（FDA）已接受其上市申请的审查，该申请旨在批准百时美施贵宝公司的Opdivo和Yervoy联合疗法，作为结直肠癌患者的一线治疗选择。
** FDA将于6月23日前做出决定
** Opdivo plus Yervoy已被批准用于治疗皮肤癌、肺癌、肾癌、结肠癌和食道癌。
** BMY 在过去 12 个月中上涨了约 10
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.